A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors

NCT03693014 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

69

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Cancer
Melanoma Cancer
Lung Cancer
Bladder Cancer
Renal Cancer
Head/Neck Cancers

Interventions

RADIATION: Stereotactic Body Radiotherapy
BIOLOGICAL: Ipilimumab, Nivolumab, Pembrolizumab or Atezolizumab

Sponsor

Memorial Sloan Kettering Cancer Center